氯胺酮用于重症急性脑损伤患者:随机临床试验的系统评价、Meta分析与试验序贯分析
该系统评价纳入5项随机临床试验(共149例)比较氯胺酮与舒芬太尼、芬太尼、其他镇静药或生理盐水。所有结局总体高偏倚风险。氯胺酮与舒芬太尼或芬太尼相比,发生1项及以上严重不良事件的比例无差异(相对危险度1.45,95%CI 0.81-2.58;极低确定性)。试验序贯分析显示需要进一步试验。关于氯胺酮对功能结局和严重不良事件影响的证据水平极低,氯胺酮可能显著、中等或完全不影响这些结局,需要大型低偏倚风险随机临床试验。
要点
- 5项随机试验共149例重症急性脑损伤患者,比较氯胺酮与舒芬太尼、芬太尼、其他镇静药或生理盐水,所有结局总体高偏倚风险。
- 氯胺酮与舒芬太尼或芬太尼相比,1项及以上严重不良事件比例无差异(RR 1.45,95%CI 0.81-2.58;极低确定性)。
- 关于氯胺酮对功能结局和严重不良事件影响的证据水平极低,氯胺酮可能显著、中等或完全不影响这些结局。
- 试验序贯分析显示需要进一步试验;需要大型低偏倚风险随机临床试验。
适用人群与场景
- 重症急性脑损伤患者。
研究设计与关键结果
- 系统评价纳入5项随机临床试验,比较氯胺酮(任何方案)与安慰剂、无干预或任何对照药物,共149例重症急性脑损伤患者。
- 对照药物包括舒芬太尼、芬太尼、其他镇静药或生理盐水。
- 所有结局总体高偏倚风险。
- 主要结局为不良功能结局比例、发生1项及以上严重不良事件的比例和生活质量。
- 氯胺酮与舒芬太尼或芬太尼相比,发生1项及以上严重不良事件的比例无差异(相对危险度1.45,95%CI 0.81-2.58;极低确定性)。
- 试验序贯分析显示需要进一步试验。
证据类型、等级与局限
- 证据类型:随机临床试验的系统评价与Meta分析及试验序贯分析;证据确定性采用推荐分级的评估、制定与评价(GRADE)评估。
- 关于氯胺酮对功能结局和严重不良事件影响的证据水平极低。
- 所有结局总体高偏倚风险。
- 试验序贯分析显示需要进一步试验。
- 需要大型低偏倚风险随机临床试验。
对床旁实践的改变
- 作者认为,关于氯胺酮对重症急性脑损伤患者功能结局和严重不良事件影响的证据水平极低,氯胺酮可能显著、中等或完全不影响这些结局。
- 作者认为,需要大型低偏倚风险随机临床试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with severe acute brain injury have a high risk of a poor clinical outcome due to primary and secondary brain injury. Ketamine reportedly inhibits cortical spreading depolarization, an electrophysiological phenomenon that has been associated with secondary brain injury, making ketamine potentially attractive for patients with severe acute brain injury. The aim of this systematic review is to explore the current literature regarding ketamine for patients with severe acute brain injury.
METHODS: We systematically searched international databases for randomized clinical trials comparing ketamine by any regimen versus placebo, no intervention, or any control drug for patients with severe acute brain injury. Two authors independently reviewed and selected trials for inclusion, extracted data, assessed risk of bias, and performed analysis using Review Manager and Trial Sequential Analysis. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation. The primary outcomes were the proportion of participants with an unfavorable functional outcome, the proportion of participants with one or more serious adverse events, and quality of life.
RESULTS: We identified five randomized trials comparing ketamine versus sufentanil, fentanyl, other sedatives, or saline (total N = 149 participants). All outcomes were at overall high risk of bias. The proportions of participants with one or more serious adverse events did not differ between ketamine and sufentanil or fentanyl (relative risk 1.45, 95% confidence interval 0.81-2.58; very low certainty). Trial sequential analysis showed that further trials are needed.
CONCLUSIONS: The level of evidence regarding the effects of ketamine on functional outcome and serious adverse events in patients with severe acute brain injury is very low. Ketamine may markedly, modestly, or not at all affect these outcomes. Large randomized clinical trials at low risk of bias are needed.
参考来源
- Andreasen TH, Madsen FA, Barbateskovic M, et al. Ketamine for Critically Ill Patients with Severe Acute Brain Injury: A Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. Neurocrit Care. 2024. PMID: 39085508. doi:10.1007/s12028-024-02075-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。